Online inquiry

IVTScrip™ mRNA-Anti-CD19, RB4v1.2(Cap 0, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ13659MR)

This product GTTS-WQ13659MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets CD19 gene. The antibody can be applied in Acute lymphocytic leukemia (ALL) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_001178098.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 930
UniProt ID P15391
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD19, RB4v1.2(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ13659MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ3652MR IVTScrip™ mRNA-Anti-FGFR2, BAY 1187982(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA BAY 1187982
GTTS-WQ15939MR IVTScrip™ mRNA-Anti-Felcat NGF, ZTS-00084768(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ZTS-00084768
GTTS-WQ3862MR IVTScrip™ mRNA-Anti-IL6R, BCD-089(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BCD-089
GTTS-WQ10766MR IVTScrip™ mRNA-Anti-FGFR4, M-70(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA M-70
GTTS-WQ11255MR IVTScrip™ mRNA-Anti-CD274, MEDI4736(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA MEDI4736
GTTS-WQ7201MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-8A-F9Z CAR(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA FMC63 scFv-8A-F9Z CAR
GTTS-WQ13750MR IVTScrip™ mRNA-Anti-ANGPTL3, REGN 1500(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA REGN 1500
GTTS-WQ4909MR IVTScrip™ mRNA-Anti-TNFRSF17, C11D5.3 scFv-8A-F9Z CAR(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA C11D5.3 scFv-8A-F9Z CAR
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW